Objectives Current tuberculosis (TB) control strategies face limitations, such as low antibiotic treatment compliance and a rise in multidrug resistance. Furthermore, the lack of a safe and effective vaccine compounds these challenges. The limited efficacy of existing vaccines against TB underscores the urgency for innovative strategies, such as immunoinformatics. Consequently, this study aimed to design a targeted multi-epitope vaccine against TB infection utilizing an immunoinformatics approach.
Methods The multi-epitope vaccine targeted Ag85A, Ag85B, ESAT-6, and CFP-10 proteins. The design adopted various immunoinformatics tools for cytotoxic T lymphocyte (CTL), helper T lymphocyte (HTL), and linear B lymphocyte (LBL) epitope prediction, the assessment of vaccine characteristics, structure modeling, population coverage analysis, disulfide engineering, solubility prediction, molecular docking/dynamics with toll-like receptors (TLRs), codon optimization/cloning, and immune simulation.
Results The multi-epitope vaccine, which was assembled using 12 CTL, 25 HTL, and 21 LBL epitopes associated with CpG adjuvants, showed promising characteristics. The immunoinformatics analysis confirmed the antigenicity, immunogenicity, and lack of allergenicity. Physicochemical evaluations indicated that the proteins were stable, thermostable, hydrophilic, and highly soluble. Docking simulations suggested high-affinity binding to TLRs, including TLR2, TLR4, and TLR9. In silico immune simulation predicted strong T cell (cytokine release) and B cell (immunoglobulin release) responses.
Conclusion This immunoinformatics-designed multi-epitope vaccine targeting Ag85A, Ag85B, ESAT-6, and CFP-10 proteins showed promising characteristics in terms of stability, immunogenicity, antigenicity, solubility, and predicted induction of humoral and adaptive immune responses. This suggests its potential as a prophylactic and therapeutic vaccine against TB.
Citations
Citations to this article as recorded by
Multidrug-resistant tuberculosis: a comprehensive review of pathogenesis, drug resistance, current treatment and future prospects Shweta Tiwari, Ankit Kumar Singh, Aarshu Acharya, Joyabroto Ghosh, Rashmi Prabha Singh Archives of Microbiology.2026;[Epub] CrossRef
Genome-Guided Mining and Integrated in Silico Approach Uncover Potential of Streptomyces Secondary Metabolites as Multi-Target Agents Against Candida albicans Biofilm Formation Ismail Ismail, Sylvia Utami Tunjung Pratiwi, Ema Damayanti, Jaka Widada, Ysrafil Ysrafil, Syamsu Nur, Abdul Halim Umar, Ira Handayani, Shanti Ratnakomala Network Modeling Analysis in Health Informatics an.2026;[Epub] CrossRef
Domain arrangement–driven immunogenicity of a computationally designed mRNA vaccine targeting PPE68, IrtA, and PE9 of Mycobacterium tuberculosis Theerawat Dobutr, Elena Stylianou, Helen McShane, Nawamin Pinpathomrat Scientific Reports.2026;[Epub] CrossRef
In silico framework for designing and validating a multi-stage subunit vaccine against Tuberculosis using reverse vaccinology approach Ayesha Liaqat, Kubra Dastgir, Muhammad Sajjad, Hafiz Muzzammel Rehman, Muhammad Waheed Akhtar, Masoud Foroutan PLOS One.2026; 21(8): e0356788. CrossRef
Computationally guided multi-epitope vaccine design targeting oncoprotein BZLF1, EBNA1, LMP1, and LMP2 for of EBV associated gastric cancer Elvin Delonio, Ysrafil Ysrafil, Herlina Eka Shinta, Sari Eka Pratiwi Journal of the Egyptian National Cancer Institute.2026;[Epub] CrossRef
Antigen 85B of Mycobacterium tuberculosis: From Immunodominant Antigen to Vaccine Candidate Vivek Chauhan, Gaytri Mahajan, Rakesh Kumar, Shrikanth S. Gadad, Subhash C. Chauhan, Chinnaswamy Jagannath, Subramanian Dhandayuthapani Vaccines.2026; 14(9): 811. CrossRef
Immunogenicity and protective efficacy of recombinant BCG expressing a multi-epitope vaccine against mycobacterium tuberculosis Xuan-ji Zhang, Jia-rui Luo, Ting-ting Tian, Juan Shi, Zheng-long Chai, Chuang Li, Si-yu Zhang, Tao Qu, Feng-bo Zhang, Yue-jie Zhu Frontiers in Cellular and Infection Microbiology.2026;[Epub] CrossRef
Computational systems immunology and multi-scale modeling for the design of a Multi-Epitope Vaccine (MEV) against emerging multidrug-resistant Klebsiella michiganensis Rasha Assad Assiri, Fayez M. Saleh, Sher Muhammad, Emmanuel O. Fenibo, Tonderayi Matambo International Microbiology.2026;[Epub] CrossRef
In Silico Targeting and Immunological Profiling of PpiA in Mycobacterium tuberculosis: A Computational Approach Mohammad J. Nasiri, Lily Rogowski, Vishwanath Venketaraman Pathogens.2025; 14(4): 370. CrossRef
New Advances in the Development and Design of Mycobacterium tuberculosis Vaccines: Construction and Validation of Multi-Epitope Vaccines for Tuberculosis Prevention Osnat Barazani, Thomas Erdos, Raafi Chowdhury, Gursimratpreet Kaur, Vishwanath Venketaraman Biology.2025; 14(4): 417. CrossRef
In-silico
epitope-based vaccines design: progress, challenges and the road ahead
Federica Cernuto, Avisa Maleki, Giulia Russo, Valentina Di Salvatore, Francesco Pappalardo Expert Opinion on Drug Discovery.2025; 20(12): 1701. CrossRef
Design of multi-epitope-based therapeutic vaccine candidates from HBc and HBx proteins of hepatitis B virus using reverse vaccinology and immunoinformatics approaches Patricia Gita Naully, Marselina Irasonia Tan, Husna Nugrahapraja, Aluicia Anita Artarini, Reza Aditama, Ernawati Arifin Giri-Rachman, Sheikh Arslan Sehgal PLOS ONE.2024; 19(12): e0313269. CrossRef
First
Prev
